The discrepancy between supply and demand in health care today requires that psychiatrists and other providers of patient care expand their traditional role from one of patient advocate to one of allocator of care.
In this new role, the care provider must consider not only the efficacy and safety of a therapeutic regimen, but also its impact on society in terms of quality of life and cost-effectiveness.
A variety of pharmacoeconomic analysis methodologies have been used to assess the economic and quality of life consequences of alternate treatment strategies.
A clinical decision analysis model that takes into account compliance rates and associated rehospitalization was used to compare the direct treatment costs associated with alternate outpatient neuroleptic strategies for « revolving door » schizophrenic patients.
The antipsychotic treatment options considered were traditional oral neuroleptics (e.g., haloperidol), depot neuroleptics (e.g., haloperidol decanoate), and « atypical » oral agents (e.g., risperidone). (...)
Mots-clés Pascal : Schizophrénie, Psychose, Chimiothérapie, Halopéridol, Psychotrope, Neuroleptique, Rispéridone, Traitement, Analyse coût, Economie santé, Epidémiologie, Modèle, Prise décision, Rôle thérapeutique, Homme, Butyrophénone dérivé
Mots-clés Pascal anglais : Schizophrenia, Psychosis, Chemotherapy, Psychotropic, Neuroleptic, Treatment, Cost analysis, Health economy, Epidemiology, Models, Decision making, Therapeutic role, Human, Butyrophenone derivatives
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0413772
Code Inist : 002B02B03. Création : 10/04/1997.